Vaccine Contract Manufacturing Market
Report Highlights
Vaccine Contract Manufactuaring Market Size And Forecast
Vaccine Contract Manufacturing Market was valued at USD 2.0 Billion in 2018 and is projected to reach USD 3.7 Billion by 2026, growing at a CAGR of 8.2% from 2019 to 2026.
Global Vaccine Contract Manufacturing Market Outlook
The major factors contributing in the growth of the global vaccine contract manufacturing market includes decreased time to market, cost benefits in infrastructure, and operational benefits. Moreover, the advancements in technology, including the introduction of new expression systems such as GPEx and EB66 cell lines and cell culture media platforms are some other major factors that are expected to propel the market growth. On the flip side, few large firms consider outsourcing risky due to loss of strategic control and limited management control. Due to this, large pharma companies choose to maintain their manufacturing operations in-house. This factor is expected to hamper the global adoption of contract services.
Global Vaccine Contract Manufacturing Market Competitive Landscape
The Global Vaccine Contract Manufacturing Market study report will provide a valuable insight with an emphasis on global market including some of the major players such as Merck KGaA, Lonza, IDT Biologika GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Cytovance Biologics, Catalent, Inc., Ajinomoto Althea, Inc., Albany Molecular Research, Inc., PRA Health Sciences, and ICON plc.
Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. It has large database which includes the latest content from renowned authors and publications worldwide. It also provides customized Data and Reports according to the need of the client.